Atara Biotherapeutics to Present at Three Upcoming Investor Conferences
May 24 2017 - 8:00AM
Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that the
Company will present at three upcoming investor conferences in
June:
- Jefferies 2017 Global Healthcare Conference
- Isaac Ciechanover, M.D., the Company's President and Chief
Executive Officer, will present a corporate overview on Tuesday,
June 6, 2017 at 3:30 p.m. ET. The conference will be held at the
Grand Hyatt Hotel in New York, NY.
- Goldman Sachs 38th Annual Global Healthcare
Conference
- Chris Haqq, M.D., Ph.D., the Company’s Executive Vice President
of Research and Development and Chief Scientific Officer, will
participate in a fireside chat discussion on Tuesday, June 13, 2017
at 4:00 p.m. PT. The conference will be held at the Terranea Resort
in Rancho Palos Verdes, CA.
- JMP Securities 2017 Life Sciences Conference
- John Craighead, Ph.D., the Company’s Vice President of Investor
Relations and Corporate Communications, will participate in a panel
discussion entitled “Immuno-oncology: From the Lab to the Clinic”
on Wednesday, June 21, 2017 at 11:00 a.m. ET. The Conference will
be held at the St. Regis Hotel in New York, NY.
Live webcasts of the presentations at the Jefferies and Goldman
Sachs healthcare conferences will be available by visiting the
Investors section of the Atara Bio website at www.atarabio.com.
Archived replays of the webcasts will be available on the Company's
website for 14 days following each presentation.
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. is a biotechnology company
developing T-cell immunotherapies for patients with severe and
life-threatening diseases who have been underserved by scientific
innovation, with a focus on cancer and autoimmune and infectious
diseases. Atara's “Off-the-Shelf” allogeneic T-cell
immunotherapy platform harnesses the power of the immune system to
recognize and attack cancer cells and cells infected with certain
viruses. Atara’s most advanced product candidate, ATA129, for
cancer patients with rituximab refractory Epstein-Barr virus (EBV)
associated Post-Transplant Lymphoproliferative Disease (EBV-PTLD)
and other EBV positive solid tumors is expected to enter Phase 3
clinical studies in 2017. The company’s clinical stage
pipeline also includes cytotoxic T-cells (CTL) targeting Wilms
Tumor 1 (WT1), or ATA520, and Cytomegalovirus (CMV), or
ATA230. Atara’s next generation T-cell immunotherapy for
autoimmune disease is an EBV-specific CTL product candidate, or
ATA188, that selectively targets specific antigens of EBV believed
to be important for the potential treatment of multiple sclerosis
(MS).
INVESTOR & MEDIA CONTACTS:
Investors:
John Craighead, Atara Biotherapeutics
650-491-5806
jcraighead@atarabio.com
Steve Klass, Burns McClellan
212-213-0006 x331
sklass@burnsmc.com
Media:
Justin Jackson, Burns McClellan
212-213-0006 x327
jjackson@burnsmc.com
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Apr 2023 to Apr 2024